VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder


VYNE Therapeutics Inc VYNE has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disorder of the skin.

  • In the preclinical model, pan-bromodomain and extra-terminal (BET) inhibitor VYN201 reduced the expression of key pro-inflammatory biomarkers relevant to the pathogenesis of vitiligo.
  • It also demonstrated a marked reduction in melanocyte loss.
  • Vitiligo is characterized by increased MMP-9 secretion and soluble E-cadherin2, resulting in a loss of pigment in the skin.
  • Related: VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal.
  • In the study, reconstituted human epithelial skin cultures were stimulated with Tumor Necrosis Factor-alpha (TNF-α) and Interferon-gamma (IFN-ɣ) cytokines to induce a vitiligo phenotype.
  • The stimulated cultures were topically treated with vehicle VYN201 at varying concentrations, or active control, topical ruxolitinib cream.
  • Applications with VYN201 resulted in statistically significant reductions in MMP-9 when compared to vehicle, with a 94.7% reduction in secreted MMP-9 for the VYN201 1% treatment.
  • VYN201 also resulted in statistically significant reductions in the release of soluble E-cadherin relative to the vehicle, with a 32.6% reduction in soluble E-cadherin for the VYN201.
  • Price Action: VYNE shares are up 1.82% at $0.52 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!